The goal of Tabula Rasa HealthCare’s (TRHC) Precision Pharmacotherapy Research & Development Institute is to innovate and redefine the science of medication safety in order to optimize medication use.
The Institute’s charter includes:
- Maintenance, update, and development of TRHC’s current technology products (e.g., Matrix, Medication Risk Score, etc.)
- New products based on pharmacokinetics/pharmacodynamics/pharmacogenomics (PK/PD/PGx), including transporter and receptor genes, etc.
- Publications related to PK/PD/PGx science.
- Research, such as drug-induced Long QT Syndrome, pharmacogenomics and phenoconversion, disease states and enzyme activity, peer-reviewed funded research, contract research organization funded initiatives, etc.
For more information, contact email@example.com.
Jacques Turgeon, BPharm, PhD, and Veronique Michaud, BPharm, MSc, PhD, are respectively Chief Executive Officer and Chief Operating Officer of the Institute. The Institute is based in the Lake Nona Medical City in Orlando, Florida. Learn more >
MedWise™ identifies accumulative multi-drug interactions to help manage patients’ medication regimens. EireneRX® is a medication decision-support and e-prescribing platform. NIARx, University Edition of MedWise, facilitates the cognitive practice of pharmacy through case-based learning. Learn more >
The Institute’s research vision comprises the emerging research initiatives that include bioinformatics, biomedical engineering systems, nanoscale science, patient-specific information, data-driven technologies and solutions, and translational research. Learn more >
Institute leadership is recognized for outstanding clinical research and publications. Learn more >
The Institute is currently actively recruiting numerous individuals with excellent credentials and expertise in pharmacometrics, pharmacogenomics, and drug metabolism. These opportunities offer collaboration with internationally renowned researchers. Please visit the TRHC Careers page.